Professor Raymond Reilly
PhD | Principal Investigator raymond.reilly@utoronto.ca Dr. Reilly is a licensed pharmacist in Ontario (Part B) and Full Professor and Director, Centre for Pharmaceutical Oncology at the Leslie Dan Faculty of Pharmacy at the University of Toronto. He received his BSc degree in pharmacy and MSc in nuclear pharmacy from the University of Toronto. He subsequently completed a nuclear pharmacy residency at Chedoke-McMaster Hospital in Hamilton, Ontario and practiced as a nuclear pharmacist at the University Health Network. He then obtained his PhD in medical biophysics from the University of Toronto and was appointed full-time to the University of Toronto in 2003. Dr. Reilly has published 141 scientific papers, 7 book chapters and two books, three Clinical Trial Applications and 120 abstracts. He has given 75 invited presentations in the areas of molecular imaging and targeted radiotherapy of cancer. He is training/has previously trained 15 PhD and 12 MSc students, 12 post-doctoral fellows, 3 research associates and 7 research technicians and 42 undergraduate research students. He teaches courses on pharmaceutical analysis and clinical laboratory medicine as well as medical imaging to undergraduate pharmacy students, and a graduate course on radiopharmaceutical science. In 2005, Dr. Reilly received the AFPC Pfizer Career Research Award, which is the highest award given annually to pharmacy professors in Canada for major contributions to research and education in the pharmaceutical sciences. |
Dr. Conrad Chan
PhD | Senior Research Associate and Laboratory Manager conrad.chan@utoronto.ca Dr. Chan is a molecular biologist and experimental therapeutics scientist. He received his BSc degree in biochemistry and PhD degree in medicine (rheumatology) from the University of Birmingham, U.K. Dr. Chan is investigating the treatment of EGFR or HER2 positive breast cancer with Auger electron-emitting radioimmunotherapeutic agents. He is supporting a Phase I clinical trial of molecular imaging of the response to trastuzumab (Herceptin) in HER2-positive breast cancer patients. He is also responsible for mentoring graduate students and other trainees in conducting their research and for managing the operations of LMIR. |
Dr. Zhongli Cai
PhD | Senior Research Associate and Radiation Safety Coordinator zhongli.cai@utoronto.ca Dr. Cai is a radiobiologist and a radiation chemist. She received a BSc degree in Applied Chemistry, an MSc degree in Radiation Chemistry and a PhD degree in Radiochemistry from Peking University, China and a PhD degree in Radiobiology from the Université de Sherbrooke, Quebec. Dr. Cai is studying 111In-labeled and HER2-targeted gold nanoparticles ("gold nanobombs") for localized radiotherapy of breast cancer as well as the radiation dosimetry of targeted radiotherapeutics for cancer. Dr. Cai is also responsible for radiation safety at LMIR. |
Valerie Facca
BSc | PhD Graduate Student valerie.facca@mail.utoronto.ca Valerie Facca is an experimental radiotherapeutics scientist in training. Valerie received her BSc in Pharmaceutical Chemistry and has industry experience studying vaccine stability and in developing commercial immune cell separation systems. She joined the LMIR team as an undergraduate thesis student in 2017 working on a SPECT imaging probe for HER2-positive breast cancer, and in 2018 joined the lab as a PhD student where she will be developing 111In-labeled monoclonal antibodies for the treatment and prevention of metastatic triple-negative breast cancer with Auger electron radioimmunotherapy. |
Constantine Georgiou
BSc | PhD Graduate Student constantine.georgiou@mail.utoronto.ca Constantine Georgiou is a molecular imaging and radiotherapeutics scientist in training. He obtained his BSc degree in Pharmaceutical Chemistry from the University of Toronto where he was selected as the winner for the Leslie Dan Faculty of Pharmacy's Undergraduate Summer Research Program poster presentation in 2018. Constantine joined the LMIR team in 2018 as an MSc student where he will be developing a brachytherapy source that uses radiolabeled gold nanoparticles for radiation treatment of glioblastoma. |
Rella Liu
BSc | PhD Graduate Student rella.liu@mail.utoronto.ca Rella Liu is a targeted radiotherapeutics and molecular imaging scientist in training. She completed her undergraduate degree in Pharmaceutical Chemistry and joined the LMIR in summer 2018 as a Leslie Dan Faculty of Pharmacy Undergraduate Summer Research Program student. Rella is currently an MSc student working on developing a combined immunotherapy and radiation nanomedicine for local treatment of metastases from triple-negative breast cancer. |
Misaki Kondo
BSc | PhD Graduate Student misaki.kondo@mail.utoronto.ca Misaki Kondo is an experimental radioimmunotherapeutic scientist in training. Misaki received her BSc Degree in Pharmaceutical Chemistry from the University of Toronto, where she investigated the regulatory expression of folate transporters at the blood-brain barrier by nuclear receptors. She joined the LMIR team in 2019 as a PhD student where she will be investigating the uptake of 111In-NLS-trastuzumab at the blood-brain barrier in combination with focused ultrasound for the treatment of brain metastases from HER2-positive breast cancer. |
Stephanie Borlase
BSc | MSc | PhD Graduate Student stephanie.borlase@mail.utoronto.ca Stephanie Borlase is an experimental radiotherapeutics scientist in training. Stephanie received her BSc in Biochemistry and her MSc in Biochemistry and Medical Genetics from the University of Manitoba, where she explored new targeted therapies for Sonic Hedgehog (SHH) medulloblastoma. Stephanie joined the LMIR team in 2022 as a PhD student where she will be developing 89Zr-labeled pembrolizumab for the treatment of brain metastases from lung cancer in combination with MRI-guided focused ultrasound. |
Madeline Brown
BScH | MSc Graduate Student madeline.brown@mail.utoronto.ca Madeline is a molecular imaging and radiotherapeutics scientist in training. She has obtained her undergraduate degree in Life Sciences with a specialization in Drug Development and Human Toxicology from Queens University. Madeline joined the LMIR team in 2022 as an MSc student where she will be investigating the potential of 197Hg labeled gold nanoparticles as a radiation treatment for glioblastoma multiforme. |
Arthur Chu
Research Project Student Arthur Chu is working on a 64Cu project with Dr. Conrad Chan. Arthur is the webmaster of LMIR. |
Alumni - Graduate Students
Felix Ho, MSc Minou Behboudi, MSc Anthony Ku, PhD Luke Kwon , PhD Noor Alsaden, PhD Sadaf Aghevlian, PhD Priscilla Lai, PhD Amanda (Amy) Boyle, PhD Karen Lam, PhD Vanessa Prozzo, MSc Simmyung Yook, PhD Ghislaine Ngo Ndjock Mbong, PhD Dane Bergström, MSc Eva J. Razumienko, PhD Niladri Chattopadhyay, PhD Kristin McLarty, PhD Danny Costantini, PhD Shahjereen Shahidullah, MSc Meiduo Hu, PhD Ying Tang, PhD Navneet Mehta, MSc Rommel Domingo, MSc Teresa Alvarez-Diez, PhD Wilson Ngai, MSc Olayinka Akinlolu, MSc Aisha Fasih, MSc Catherine Gao, MSc |
Alumni - Post-doctoral Fellows
Noor Alsaden, PhD Bart Cornelissen, PhD Veerle Kersemanns, PhD Humphrey Fonge, PhD Andrew Green, PhD Ying He, PhD Jeffrey Leyton, PhD Alumni - Research Technicians Amanda (Amy) Boyle Deborah Scollard, R.T.N.M. Hridya Mondal Reza Kiaresh Allison Yu Kristy Baily |
Project Students
2022 Nubaira Forkan 2021 Nakita Gopal 2020 Felix Ho 2018-2019 Erin Li Rella Liu 2017-2018 Valerie Facca Jenny Crick 2012-2013 Arman Zereshkian 2011-2012 Yongkyu (Luke) Kwon 2010-2011 Yongkyu (Luke) Kwon Catherine Gao Summer Students
2022 Anna Nguyen 2018 Rella Liu 2017 Domenico Arcuri 2016 Zarah Khan 2014 Guihong Teng 2013 Arman Zereshkian Chen (Jason) Chen 2012 Arman Zereshkian Kaiyu (Kyle) Yang Yongkyu (Luke) Kwon |
2011
Dane Bergström Lindsay Dryden Yongkyu (Luke) Kwon Maryam Mortazavi 2010 Androu Arsanious Wenchao Jessica Liu Andrew Wong Maryam Mortazavi 2008 Serena Smith 2006-2007 Ruifen Su (lead to Excellence in Summer Research Project Award) 2004 April Eryou 2000 Karen Bai |